MA39990A - Induction de régénération cardiaque par micro-arn - Google Patents
Induction de régénération cardiaque par micro-arnInfo
- Publication number
- MA39990A MA39990A MA039990A MA39990A MA39990A MA 39990 A MA39990 A MA 39990A MA 039990 A MA039990 A MA 039990A MA 39990 A MA39990 A MA 39990A MA 39990 A MA39990 A MA 39990A
- Authority
- MA
- Morocco
- Prior art keywords
- microrna
- induction
- cardiac regeneration
- regeneration
- relates
- Prior art date
Links
- 108091070501 miRNA Proteins 0.000 title abstract 3
- 230000000747 cardiac effect Effects 0.000 title abstract 2
- 230000008929 regeneration Effects 0.000 title abstract 2
- 238000011069 regeneration method Methods 0.000 title abstract 2
- 230000006698 induction Effects 0.000 title 1
- 230000001737 promoting effect Effects 0.000 abstract 2
- 210000004413 cardiac myocyte Anatomy 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000003278 mimic effect Effects 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 210000000130 stem cell Anatomy 0.000 abstract 1
- 230000017423 tissue regeneration Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0657—Cardiomyocytes; Heart cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0375—Animal model for cardiovascular diseases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/65—MicroRNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Rheumatology (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Cardiology (AREA)
- Developmental Biology & Embryology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
L'invention concerne des compositions et des méthodes permettant de favoriser la prolifération cellulaire et la dé-différenciation des cellules en cellules souche pour favoriser la régénération tissulaire. Plus particulièrement, l'invention concerne l'administration transitoire d'un microarn (mir) ou de son mimétique pour promouvoir la régénération cardiaque et la prolifération de cardiomyocytes.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461994250P | 2014-05-16 | 2014-05-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA39990A true MA39990A (fr) | 2015-11-19 |
Family
ID=54480744
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA039990A MA39990A (fr) | 2014-05-16 | 2015-05-15 | Induction de régénération cardiaque par micro-arn |
Country Status (9)
Country | Link |
---|---|
US (1) | US10590419B2 (fr) |
EP (1) | EP3143123B1 (fr) |
CY (1) | CY1123144T1 (fr) |
DK (1) | DK3143123T3 (fr) |
ES (1) | ES2769030T3 (fr) |
MA (1) | MA39990A (fr) |
PL (1) | PL3143123T3 (fr) |
PT (1) | PT3143123T (fr) |
WO (1) | WO2015175889A1 (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20200108013A1 (en) * | 2017-03-31 | 2020-04-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods for cardiac regeneration |
JP7279953B2 (ja) * | 2017-12-08 | 2023-05-23 | ユニバーシティ オブ ワシントン | カルジオリピンのリモデリング及び心筋細胞の成熟を検出、及び促進する方法及び組成物、並びにミトコンドリア機能障害治療の関連する方法 |
US11179479B2 (en) | 2018-01-05 | 2021-11-23 | Animatus Biosciences, Llc | Enhanced cardiomyocyte regeneration |
US20220251552A1 (en) * | 2019-03-25 | 2022-08-11 | The Trustees Of The University Of Pennsylvania | Regenerative Therapy Based on miRNA-302 Mimics for Enhancing Host Recovery from Pneumonia Caused by Streptococcus pneumoniae |
EP3936616A1 (fr) | 2020-07-10 | 2022-01-12 | Charité - Universitätsmedizin Berlin | Thérapie ciblée par micro-arn pour réparation cardiaque |
CN112891619B (zh) * | 2021-01-28 | 2021-10-26 | 四川大学 | 具有选择性抑制平滑肌细胞表型转化的基因洗脱涂层材料及其制备方法 |
WO2022202930A1 (fr) * | 2021-03-23 | 2022-09-29 | 国立大学法人京都大学 | Composition et composition pharmaceutique |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE122007000007I2 (de) | 1986-04-09 | 2010-12-30 | Genzyme Corp | Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern |
US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
US6756196B2 (en) | 1999-06-28 | 2004-06-29 | Millennium Pharmaceuticals, Inc. | Molecules of the card-related protein family and uses thereof |
EP2123759B1 (fr) | 2004-02-06 | 2014-01-15 | Thermo Fisher Scientific Biosciences Inc. | ARN stabilisés en tant que contrôles de la transfection et réactifs silencieux |
US9683232B2 (en) | 2007-12-10 | 2017-06-20 | Kyoto University | Efficient method for nuclear reprogramming |
EP2229444B1 (fr) | 2008-01-16 | 2019-10-30 | Shi-Lung Lin | Génération de cellules pluripotentes de type cellules souches embryonnaires sans tumeur utilisant des agents d'arn recombinant inductible |
US20100062534A1 (en) | 2008-09-09 | 2010-03-11 | The General Hospital Corporation | Inducible lentiviral vectors for reprogramming somatic cells |
WO2011133288A1 (fr) | 2010-04-19 | 2011-10-27 | The Trustees Of The University Of Pennsylvania | Induction par micro-arn de cellules souches pluripotentes et leurs utilisations |
EP2591095B1 (fr) | 2010-07-08 | 2016-04-27 | Duke University | Reprogrammation directe de cellules en un devenir de cardiomyocytes |
DK2790736T3 (en) * | 2011-12-12 | 2018-05-07 | Oncoimmunin Inc | In vivo delivery of oligonucleotides |
ITRM20110685A1 (it) * | 2011-12-23 | 2013-06-24 | Internat Ct For Genetic En Gineering And | Microrna per la rigenerazione cardiaca attraverso l induzione della proliferazione dei miociti cardiaci |
-
2015
- 2015-05-15 PL PL15792355T patent/PL3143123T3/pl unknown
- 2015-05-15 WO PCT/US2015/030990 patent/WO2015175889A1/fr active Application Filing
- 2015-05-15 MA MA039990A patent/MA39990A/fr unknown
- 2015-05-15 EP EP15792355.8A patent/EP3143123B1/fr active Active
- 2015-05-15 ES ES15792355T patent/ES2769030T3/es active Active
- 2015-05-15 PT PT157923558T patent/PT3143123T/pt unknown
- 2015-05-15 DK DK15792355.8T patent/DK3143123T3/da active
- 2015-05-15 US US15/311,765 patent/US10590419B2/en active Active
-
2020
- 2020-01-21 CY CY20201100046T patent/CY1123144T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
CY1123144T1 (el) | 2021-10-29 |
ES2769030T3 (es) | 2020-06-24 |
US10590419B2 (en) | 2020-03-17 |
US20170096671A1 (en) | 2017-04-06 |
PT3143123T (pt) | 2020-02-04 |
EP3143123A4 (fr) | 2017-10-11 |
WO2015175889A1 (fr) | 2015-11-19 |
EP3143123B1 (fr) | 2019-11-27 |
EP3143123A1 (fr) | 2017-03-22 |
DK3143123T3 (da) | 2020-02-10 |
PL3143123T3 (pl) | 2020-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA39990A (fr) | Induction de régénération cardiaque par micro-arn | |
MX2023000818A (es) | Anticuerpos anti-antigeno 4 del linfocito t citotoxico (ctla-4) y metodos para uso de los mismos. | |
MX2022013114A (es) | Inhibidores de diana de rapamicina en celulas de mamifero de complejo 1 (mtorc1). | |
TWD179057S (zh) | 充電器 | |
MX2017005252A (es) | Metodos para la preparacion de ribosidos. | |
MX2017007196A (es) | Fibroblastos de embrion de pollo inmortalizados. | |
MX369645B (es) | Anticuerpos multiespecificos. | |
PH12016501441A1 (en) | Chimeric alkaline phosphate-like proteins | |
BR112016016916A2 (pt) | método de tratamento de angiodema hereditário (hae) | |
EP3198004A4 (fr) | Cellules souches pluripotentes induites naïves indépendantes de la signalisation tgfss, procédés de production et utilisation | |
TWD171711S (zh) | 端子 | |
MX2016009858A (es) | Fusiones anti proteína convertasa subtilisina/kexina tipo 9 (anti-pcsk9)n péptido 1 similar a glucagón (glp-1) y métodos de uso. | |
EP3118307A4 (fr) | Activateur de cellules souches mésenchymateuses, cellules mésenchymateuses activées, et leur procédé de production | |
EP3170892A4 (fr) | Procédé d'accroissement d'activité de substrat de culture cellulaire pour fragment de laminine | |
MX2017000142A (es) | Celulas estromales mesenquimatosas para tratar el sindrome de respuesta inflamatoria sistemica. | |
IL251616B (en) | Methods and compounds for the treatment and prevention of muscle mass loss | |
MY183321A (en) | Microorganism producing o-acetyl-homoserine and method for producing o-acetylhomoserine using the same | |
MX2016015163A (es) | Biomarcadores mit y metodos para su uso. | |
HK1249862A1 (zh) | 多能性幹細胞遷移促進劑 | |
NZ730124A (en) | A method of predicting risk of recurrence of cancer | |
TWD175028S (zh) | 輸送帶刮刀之基座 | |
IN2014DN00254A (fr) | ||
SG10202010615QA (en) | Method for promoting and improving properties of adipose tissue, tissue and cells obtained by said method | |
MX2017014890A (es) | Metodos de produccion de acetolactato-descarboxilasa (aldc). | |
EP3300506A4 (fr) | Utilisation de cellules souches mésenchymateuses dans le traitement de l'arthrose |